These findings, consistent with the observed radioligand uptake profiles, suggest that SSTR2-targeted theranostic approaches may offer a promising strategy for overcoming resistance and improving therapeutic outcomes in the management of HCC. This evidence concerns the gene SSTR2 and hepatocellular carcinoma.